INTERMACS DATA SHOWS PROGRESS USING MCS DEVICES IN DESTINATION THERAPY AS A PERMANENT TREATMENT OPTION FOR HEART FAILURE

Initial Results of the Destination Therapy Post-FDA-Approval Study with a Continuous Flow Left Ventricular Assist Device: A Prospective Study using the INTERMACSPrague, Czech Republic, April 18, 2012 – Today researchers will report initial findings of a post-FDA-approval study using Left Ventricular Assist Devices as destination therapy for heart failure patients.  The findings show signs that destination therapy may soon be a permanent treatment option for patients as an alternative to transplantation. A report from the U.S. Interagency Registry for Mechanically Assisted Circulatory